人类 体外 抑制作为识别免疫失衡早期状态的筛选工具

摘要

Tregs 是免疫系统的强效抑制细胞。由于缺乏定义 Tregs 的特异性表面标志物，因此对 Tregs 的定义主要基于其功能。本文描述了一种优化的 体外 一种能够识别有患1型糖尿病风险个体中免疫失衡的检测方法。

摘要

调节性T细胞（Tregs）是介导对自身抗原免疫耐受的关键因素。此外，它们在感染后免疫应答的调控中也发挥着至关重要的作用。尽管已有诸多努力试图鉴定Tregs特有的表面标志物，但其唯一独特特征仍是抑制效应T细胞增殖和功能的能力。虽然目前明确的是，仅 体外 在评估人类调节性T细胞（Treg）功能时，尽管可以使用多种检测方法，但在进行横断面研究结果评估时会遇到问题，尤其是在需要比较健康个体细胞与自身免疫性疾病患者（如1型糖尿病-T1D）分离细胞的情况下。目前各实验室在所使用的反应性T细胞的数量和类型、刺激的性质与强度、Treg与反应性T细胞的比例，以及所用抗原呈递细胞（APC）的数量和类型方面存在显著差异。 体外 抑制实验。这种变异性使得不同研究之间在评估Treg功能时难以进行比较。Treg研究领域亟需一种标准化的抑制实验方法，能够同时适用于健康个体和自身免疫性疾病患者。我们已开发出一种 体外 抑制试验显示，与存在胰腺β细胞自身免疫破坏的受试者相比，来自健康志愿者的T细胞在刺激过程中表现出极低的实验内变异性。本文主要目的是描述一种 体外 一种可实现不同受试组间比较的人源抑制试验。此外，该试验有望揭示自然调节性T细胞（nTreg）功能的轻微下降，并预测其未来可能的进一步减损，从而识别出可能从预防性免疫调节治疗中获益的个体¹以下，我们将详细描述该操作步骤中的各个环节。我们希望为该技术的标准化作出贡献 体外 用于评估Treg功能的抑制试验。此外，我们提供该试验作为识别免疫失衡早期状态以及T1D潜在功能性生物标志物的工具。

方案

1. Before setting up a suppression assay, one needs to coat tosylactivated beads with anti-human CD3 (clone UCHT1, final concentration 1μg/ml) for cell stimulation and afterwards check whether the beads are efficiently coated by setting up an in vitro proliferation assay using human T cells

1. Take 1ml of M-450 tosylactivated beads from original vial, place in magnetic stand and hold until all the beads have adhered to the side of the tube. Remove the buffer while tube is still in the magnetic stand. Take tube out of magnetic stand and add 1ml of buffer1, place the tube in magnetic stand again and remove the buffer1 while tube is in the magnetic stand; resuspend beads in 1ml of buffer1 and add 40μl of anti-human CD3, agitate at 37°C for 15 minutes, add 0.1%w/v BSA and continue agitating for next 16 hours.
2. Wash the beads in buffer2 twice for 5 minutes at 2-8°C and once in buffer3 for 5 minutes at 2-8°C using magnetic stand as explained above; remove the buffer and resuspend the beads in 1ml of buffer2; the beads are 4x10⁸/ml final concentration and ready for use.
3. Aliquot 50,000 and 25,000 PBMC/well in triplicates in a 96-well plate and add variable number of CD3-coated beads (4x10⁸beads/ml, CD3 1μg/ml, for example 1, 2, 3, 4, 5 beads/cell) in order to determine the optimal number of beads per cell. After 72 hours in culture, add 1μCi [³H] thymidine and continue incubating at 37°C for the next 16 hours. Harvest cells in Multiscreen harvest plate (Millipore), add scintillation liquid and read counts per minutes (cpm)/well using Top Count NXT (Packard, CT). Use the beads/cell ratio when cpms are above 5000 but less than 15000 to avoid overstimulation of Tregs, which might lose suppressive function. Usually, ratio of 3 beads/cell stimulates both responder and Treg cells in all subject groups tested so far^1-4.

2. PBMC isolation from whole blood from healthy donors or from human leukopacks or buffy coat (BC) usually taken from healthy volunteers and available free of charge from local Blood Transfusion Centers (Figure 1)

1. Dilute the BC (˜50ml) 1:6 with PBS (add 250ml). Now there is 300ml total volume. Slowly layer 25ml of diluted BC on top of 15ml Ficoll-Paque PLUS added to 50ml Falcon tubes, without disturbing the layers. Centrifuge at 800xg (1400rpm in a Sorvall centrifuge with swinging bucket rotor SH-3000) for 30 minutes at 4°C, with brakes turned off.
2. Carefully collect the PBMC layer (intermediate phase) and transfer it to a fresh 50ml Falcon tubes. Wash PBMC by filling the tubes up to 50ml with DPBS. Collect 2 cell pellets into one tube. Centrifuge at 400xg for 10 min at 4°C. Repeat washing step twice, each time combining 2 cell pellets into a single tube. Combine all cell pellets into a single 50ml tube.
3. Count PBMC using Trypan Blue exclusion test. Make a 1:10 dilution in Trypan Blue by adding 20μl of PBMC to 180μl of Trypan Blue stain. Mix well and take 20μl to count in hemacytometer immediately. Count numbers of all unstained and only blue stained cells located in two square blocks each containing 16 smaller squares. Take the average of both numbers and multiply by 10. Divide this number by 100 to get the number of PBMC/ml. Percentage of viable cells calculate as [1-(number of blue cells/number of total cells)x100]. Proceed if viability is ≥95%.

3. MACS pre-sort of CD4 T cells

1. Before proceeding, transfer 1ml of PBMC into a new tube, add 4ml of media to prepare cells for irradiation with 5000rad- these will be antigen-presenting cells (APC).
2. Centrifuge the rest of the cells at 250xg in PBS/2mM EDTA/0.5%BSA buffer for 10min at 4°C. Pour off supernatant, and resuspend cells in 4ml of PBS/2mM EDTA/0.5%BSA buffer.
3. Add 200μl of MACS anti-CD4 microbeads and incubate at 4°C for 20 minutes.
4. Wash by adding 40ml of PBS/2mM EDTA/0.5%BSA buffer and centrifuge at 250xg for 10min at 4°C. Pour off supernatant and resuspend in 8ml of degassed, room temperature PBS/2mM EDTA/0.5%BSA buffer.
5. Filter-separate the cell suspension using Pre-separation filters before loading them on an LS column.
6. Split the cell suspension and layer 4ml each over calibrated LS column (with 3ml of deggassed PBS/2mM EDTA/0.5%BSA buffer). LS column is fixed in the MidiMACS separator. Before cell suspension runs out, either re-run flowthrough or add 3ml of deggassed room temperature PBS/2mM EDTA/0.5%BSA buffer and let the buffer run through. Add more buffer until it comes out clear.
7. Pipette 5ml deggassed buffer onto the LS column, remove LS Column from the MidiMACS separator and place into a new sterile 15ml collection tube letting ˜1.0ml run through. Put the plunger into the column and slowly push the rest of the volume out.
8. Do the same with both LS columns and combine the two CD4+ fractions. Add up to 50ml PBS and count cells. Expected yield is up to 5x10⁸ cells. Centrifuge at 400xg for 10 minutes and resuspend cells well in 2ml PBS/2mM EDTA/0.5%BSA buffer.

4. Fluorescent Activated Cell Sorting (FACS) isolation (Figure 2)

1. Make a cocktail of antibodies to CD markers to the following cell surface markers (keep protected from light): 20 μl of anti-human CD8-FITC (clone RPA-T8), 20 μl of anti-human CD14-FITC (clone M5E2; LPS receptor), 20 μl of anti-human CD32-FITC (clone FLI8.26; FcγR-type II) and 6 μl of anti-human CD116-FITC (clone M5D12; GM-CSFRα chain) and, alternatively, add 40μl anti-human CD4-APCCy7 (clone RPA-T4).
2. Take 5μl out of the 2ml cell suspension and stain with 2μl of stain cocktail; this is a tube for determining the threshold (Fluorochrome Minus One-FMO)⁵.
3. Add 50 μl of anti-human CD25-PE (clone M-A251; IL-2Rα) to the stain cocktail, and add the cocktail to cell suspension and incubate at 4°C 30 minutes. Wash cells in PBS buffer, centrifuge at 400xg for 10 minutes and resuspend cells to a cell concentration of 10⁷/ml.
4. Prepare unstained cells and cells or beads stained with single fluorochrome to use as compensation control for cell sorting on FACS Aria (BD Biosciences, San Jose, NJ).
5. Acquire cells in the FMO tube which will allow the user to set the threshold for sorting of CD25+ T cells (Figure 2a). Set a gate around FITC-negative cells to exclude FITC-positive cells comprising monocytes, macrophages and all other CD4+-non-T cells (Figure 2b).
6. In a separate plot, draw gates for CD25-, CD25low and CD25high T cells-Tregs (top 1% of cells expressing the highest number of CD25) (Figure 2c). Cell subsets typically show high purity (Figure 2d, 2e and 2f).
7. Centrifuge collection tubes with cells at 400xg for 10 minutes and keep them on ice until plating.

5. Set up cell culture in 96-well plate (scheme attached as Table1) in 200μl/well

1. Aliquot 50μl of CD3-coated beads (1 μg/ml) calculated to be 3 beads/responder cell in a well, resuspended in complete media with 10% pooled human AB serum in U-bottom 96-well plates. (For example, to make 2ml media with CD3-coated, take 7.5μl from stock of CD3-coated beads -final concentration 4x10⁸/ml and dilute in 2ml of media; every 50μl will contain 75,000 beads-3beads/cell).
2. Dilute irradiated APC to 5x10⁵/ml cell concentration and add 50μl (will contain 2.5 x 10⁴ cells) into each well with previously added stimulation, including wells labeled as "Tregs only", "APC only" and "media only" in Table 1.
3. Add 2.5 x 10⁴/well CD4CD25- or CD4CD25low T cells in triplicates following design in Table 1.
4. Add Tregs to co-cultures (row B, Table 1) in the ratio 1:10 (2,500 Treg cells) and to wells labeled as "Tregs only" and incubate the plate at 37°C in CO₂ incubator with 5% CO₂, in saturated humidity for 72 hours.
5. Pulse wells with 1μCi [³H] thymidine and continue incubation at 37°C for next 16 hours.

6. Harvesting and counting

1. Harvest cells on multiscreen harvest plate using Packard filtermate harvester or alternative system.
2. Add scintillation liquid (Microscint 20), cover harvesting plate with transparent plastic cover in preparation for the final step.
3. Read counts per minutes (cpm)/well using Top Count NXT (Packard, CT) or alternative system.

7. Computing percentage of suppression

1. As cells were cultured in triplicates, average is calculated for each condition. If the coefficient of variation is >30%, the outlier is eliminated and only cpm from two wells are averaged. Percentage of suppression is obtained by computing [(s-c)/s] x 100%, where s=cpm in single culture and c=cpm in co-culture.
2. As naïve (CD25-) and in vivo activated (CD25low) effector T cells are plated as responder T cells, the difference in the ability of Tregs to suppress each of these subsets is captured and used as a potential functional prognostic indicator based on the premise that activated cells are harder to suppress.

8. Representative Results:

Great variability in the methods used and results derived from in vitro human suppression assay prompted us to perform a comprehensive study of conditions influencing the assay¹. We have developed an assay that tests not only Treg function, but also their purity, considering the low ratio between Tregs:Teffs (1:10), which we determined earlier⁶. In addition, Tregs differ in their ability to successfully suppress naïve and in vivo-activated T cells even in healthy subjects, as shown in Figure 3 and in our previous studies^2,4, which becomes more prominent if immune balance is compromised, as in subjects at risk to develop T1D. The assay worked very well in the study where we compared suppressive function of natural (nTregs), inducible (iTregs) and in vitro expanded nTregs, allowing us to compare their function between healthy control, recent-onset (RO) T1D and longstanding (LS) T1D subjects. We concluded that RO T1D subjects had better capacity of generating functional both iTregs and expanded nTregs compared to LS T1D and healthy control subjects⁷. Thus, this assay can be used as an excellent tool in the recognition of both an early and late state of immune imbalance.

Scheme 1 Schematic presentation of the steps involved in in vitro suppression assay

Figure 1. Steps of the in vitro suppression assay presented with photographs

Figure 2. Gating strategy in FACS cell isolation. a) CD25+ threshold was adjusted according to Fluorochrome Minus One (FMO), b) cells were gated as FITC-negative, c) FITC-negative cells were further gated and collected as CD+CD25-, CD+CD25low and CD+CD25high (Tregs) shown with percentages, d) FACS sorted Tregs after sorting, e) FACS sorted CD+CD25low after sorting, and f) FACS sorted CD4+CD25- T cells after sorting

Figure 3. Representative results of healthy subjects a) Representative results of counts per minute (cpm) of healthy subjects presented as single cultures for all cell subsets involved (naïve-CD25-, in vivo activated-CD25low, antigen-presenting cells-APC and regulatory T cells-Treg) as well as co-cultures of responder T cells (CD25- or CD25low) and Tregs. b) Percentage of suppression of each CD25- and CD25low responder T cells by autologous Tregs is presented for healthy control subjects (n=4). Suppression was computed as [(s-c)/s] x 100%, where s=cpm in single culture and c=cpm in co-culture. Although slight difference in capacity of Tregs to suppress responder T cells was noticed, it was not significant (paired t-test p=0.08). c) Presented are cpm of at risk subjects for each single culture, including CD25- and CD25low as responder T cells as well as APC and Tregs, and co-cultures where each responder T cell subset is seeded with Tregs (CD25-/Tregs and CD25low/Tregs). d) Percentage of suppression of each CD25- and CD25low responder T cells by autologous Tregs is presented for at risk subjects (n=4). The difference in capacity of Tregs to suppress CD25- versus CD25low responder T cells was significant (paired t-test p=0.04).

Table 1. Schematic set up of in vitro suppression assay

	1-3	4-6	7-9	10-12
A	CD4CD25-	CD4CD25low	media only	media only
B	CD4CD25- /Tregs	CD4CD25low /Tregs	Tregs only	APC only
C
D
E
F
G
H

讨论

由于抑制功能是调节性T细胞（Tregs）唯一的独特特征，因此应在同一研究及不同研究中，对疾病发展不同阶段的受试者之间可靠且一致地检测该功能。我们提供了本实验室建立的抑制实验的详细信息，以推动该实验方法的标准化。在我们 extensive 的优化研究中，我们确定使用抗人CD3包被的微珠（UCHT1克隆，浓度为1μg/ml，而非商业产品常用的5μg/ml）联合外周血单个核细胞（PBMC）作为抗原呈递细胞（APC），可提供一种天然刺激方式，有效激活受试者中的反应性T细胞和调节性T细胞¹。抗人CD3抗体的选择至关重要，因为在我们的实验中，仅Ancell公司的抗体获得了预期结果。单独使用抗人CD3与抗人CD28联合刺激不足以检测出不同受试组之间的差异（结果未显示），而PBMC可提供完整的共刺激信号谱，从而提高信号转导的可能性并实现高效刺激。

本方案既可用于白细胞浓缩物，也可用于患者血液。唯一的区别在于PBMC分离过程中需要加在Ficoll-Paque PLUS上方的血量。本实验所用培养基含有10%混合人AB型血清，我们发现该成分对实验具有显著促进作用。然而，在使用前必须...

材料

本文使用的材料清单

姓名	公司	目录编号	评论
菲可-帕克 PLUS	Amersham	17-1440-03
DPBS-1X	GIBCO, by Life Technologies	14190-144
台盼蓝	Invitrogen	15250-061
抗 CD4 磁珠	Miltenyi Biotec	130-045-101
预分离滤器	Miltenyi Biotec	130-041-407
LS 柱	Miltenyi Biotec	130-042-401
EDTA	Invitrogen	15575-020
BSA	Sigma-Aldrich	B4287
抗人 CD4-APCCy7（克隆 RPA-T4）	BD Biosciences	557852
抗人 CD25-PE（克隆 M-A251；IL-2Rα）	BD Biosciences	555432
抗人 CD8-FITC（克隆 RPA-T8）	BD Biosciences	555366
抗人 CD14-FITC（克隆 M5E2；LPS 受体）	BD Biosciences	555397
抗人 CD32-FITC（克隆 FLI8.26；FcγR II 型）	BD Biosciences	555448
抗人 CD116-FITC（克隆 M5D12；GM-CSFRα 链）	BD Biosciences	554532
Dynalbeads M-450 甲苯磺酰化磁珠	Invitrogen	140-13
抗人 CD3	Ancell	144-024
缓冲液1	自制		0.1M Na2B4O7 pH7.6
缓冲液2	自制		PBS/2mM EDTA/ 0.1% BSA pH7.4
缓冲液3	自制		0.2M Tris/0.1% BSA pH8.5
完全 RPMI 培养基	自制		RPMI 1640 培养基 2 mM L-谷氨酰胺 5 mM HEPES 100 U/μg/ml 青霉素/链霉素 0.5 mM 丙酮酸钠
[3H] 胸苷	PerkinElmer, Inc.	NET027Z005MC
人混合 AB 血清	Atlanta Biologicals	S40110
多孔收获板	EMD Millipore	MAHFC1H60
Microscint 20	PerkinElmer, Inc.	6013621